Combined THC and CBD Drops for Treatment of Crohn's Disease

Phase 1

Completed

• Conditions: Crohn's Disease
• Interventions: Drug: THC 5mg/ml and CBS 50mg/ml; Drug: Placebo

• Registration Number: NCT01826188
• Lead Sponsor: Meir Medical Center

Brief Summary

There are many reports about efficacy of Cannabis in Crohn's disease but no controlled trials. The aim of the proposed trial is to investigate the efficacy of oil containing the cannabinoids THC and CBD given by mouth for induction of remission in Crohn's disease.

Detailed Description

The investigators have recently published a retrospective observational study about the beneficial effect of cannabis in Crohn's disease. The investigators have also concluded a double blind placebo controlled study of Inhaled cannabis in the treatment of Crohn's disease. Both studies have shown significant symptomatic improvement of disease. However, objective parameters of inflammation were not measured. The question arises as to whether the observed improvement is merely symptomatic or due to a real change in inflammation. In addition, administration per os is a healthier option than smoking but the efficacy of oral cannabis was not investigated.

The aim of the proposed study in to evaluate the efficacy of drops of cannabis oil in crohn's disease patients compared to placebo. Treatment success will be defined as a decrease of at least 100 points in CDAI after 8 weeks of treatment.

Secondary aims:

1. Remission of disease i.e CDAI of less the 150 points.

2. Improvement of at least one point in Endoscopic disease activity index

3. Improvement of CRP and calprotectine

4. Improvement of blood cytokine levels

5. Improvement of at least 30 points in quality of life as measured by the SF 36. In addition the investigators will monitor side effects by questionnaires addressed to the patients and to a significant relative of the patients.

Study Timeline

• Study Start: 2013-03
• Study First Submitted: 2013-03-28
• Study First Submitted QC: 2013-04-05
• Study First Posted: 2013-04-08
• Primary Completion: 2018-06
• Study Completion: 2018-06
• Status Verified: 2019-03
• Last Update Submitted: 2019-03-07
• Last Update Posted: 2019-03-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Patients with a diagnosis of Crohn's disease of at least 3 months duration, which was proved by either endoscopy or appropriate imaging study.

2. Patients who have failed treatment with either 5 ASA or corticosteroids or immunomodulators or biologic agents, or steroid dependant patients, or patients who were treated by the above mentioned drugs and could not tolerate them due to side effects.

3. Age 20 or older.

4. Able to sign informed concent

5. Active Crohn's disease with a CDAI 200 or more.

Exclusion Criteria

1. Patients with a diagnosis of a mental disorder

2. Patients who by the judgment of their physician are likely to develop drug addiction.

3. Pregnant women or women who are intending to become pregnant

4. Patients with a known cannabis allergy

5. Patients who are not capable of giving an informed consent

6. Patients with an impending operation due to Crohn's disease.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
THC 5 mg/ml and CBD 50 mg/ml.	THC 5mg/ml and CBS 50mg/ml	olive oil containing THC 5 mg/ml and CBD 50 mg/ml. which will be taken twice daily.
Placebo	Placebo	olive oil but without any active ingredients.

Primary Outcome Measures

Name	Time	Method
Treatment sucsess will be defind as a decrease of at least 100 points in CDAI after 8 weeks of treatment.	8 weeks	The aim of the proposed study in to evaluate the efficacy of drops of cannabis oil in crohn's diseas patients compared to placebo. Treatment sucsess will be defind as a decrease of at least 100 points in CDAI after 8 weeks of treatment.

Secondary Outcome Measures

Name	Time	Method
Remission of disease	8 weeks	1. Remission of disease i.e CDAI of less the 150 points.
endoscopic improvment	8 week	2. Improvment of at least one point in Endoscopic disease activity index
Improvment of CRP and calprotectine	8 week	CRP and calprotectine will be measured before and after 8 weeks of study treatment
Improvment of blood cytokine levls	8 weeks	blood cytokine levls including IL-10, TNF, and IL 23 will be measured before and at the end of the study
Improvment of at least 30 points in quality of life as measured by the SF 36.	8 weeks	patients will answer a short form of Health related quality of life quasionnair before and at the end of the study.

Trial Locations

Locations (1)

Meir Hospital; 🇮🇱 Kfar Saba, Israel